PHAGOCYTE ENHANCEMENT THERAPY FOR ATHEROSCLEROSIS

• US 20080267909A1
• Filed: 02/22/2008
• Published: 10/30/2008
• Est. Priority Date: 08/24/2005
• Status: Abandoned Application

• Current Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Original Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Inventors: TABAS, Ira
• Application Number:
  US12/035,869
• Publication Number:
  US 20080267909A1
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 2800/323 Arteriosclerosis, Stenosis
• CPC Class Codes: G01N 33/5055 involving macrophages

Abstract

Compounds that increase phagocytosis of apoptotic macrophages or necrotic cells that are associated with advanced atherosclerotic lesions are useful for treating atherosclerosis. Methods are provided for identifying such compounds and for preventing or treating atherosclerosis by increasing phagocytosis of apoptotic macrophages associated with advanced atherosclerotic lesions.

Claims

1. A method for identifying an enhancer of phagocytic clearance of free cholesterol-induced (FC-induced) macrophages, the method comprising

(a) labeling an FC-induced apoptotic macrophage;

(b) culturing the FC-induced apoptotic macrophage in the presence of phagocytes and in the presence of a test compound, thereby providing a test sample; and

(c) determining the amount of a label present in the phagocytes in the test sample, wherein, an increase in the amount of the label in the phagocytes in the presence of the test compound compared to the amount of the label present in the phagocytes cultured with FC-induced apoptotic macrophages in the absence of the test compound indicates that the compound is an enhancer of phagocytic clearance of a FC-induced apoptotic macrophages.

5. The method of claim 1, wherein the phagocytes are derived from peritoneal macrophages.

6. The method of claim 1, wherein the FC-induced apoptotic macrophage is labeled with calcein-AM.

7. The method of claim 1, wherein the FC-induced apoptotic macrophage is labeled with annexin V.

10. The method of claim 1, wherein the apoptotic macrophage is induced by contacting the macrophage with acetyl-low density lipoprotein (acetyl-LDL) and an acyl-coenzyme A:

cholesterol acyltransferase (ACAT) inhibitor.

13. The method of any of claim 10-12, wherein the ACAT inhibitor is 58035 ACAT inhibitor.

14. The method of any of claim 1-3, wherein the increase in the amount of label present in the phagocytes of the test sample compared to the amount of label in the macrophages cultured in the absence of the test compound is at least 10%, 20%, 25%, 30%, 50%, 75%, 90%, or 100% greater than the amount of label in the macrophages cultured in the absence of the test compound.

15. The method of any of claim 1-3, wherein the macrophages of (b) are cultured in the presence of a test compound and a statin, and the amount of label present in the phagocytes in the test sample is compared to the amount of label present in the phagocytes in the absence of the test compound and in the presence of the statin.

35. The composition of claim 34, wherein the phagocyte enhancer compound is identified using the method of any of claim 1.

39. A kit comprising a composition comprising an enhancer of phagocytic clearance of FC-induced apoptotic macrophages identified using the method of claim 1, and instructions for use.

2. A method for identifying an enhancer of phagocytic clearance of free cholesterol-induced (FC-induced) macrophages, the method comprising

(a) labeling an FC-induced necrotic macrophage;

(b) culturing the FC-induced necrotic macrophage in the presence of phagocytes and in the presence of a test compound, thereby providing a test sample; and

(c) determining the amount of a label present in the phagocytes in the test sample, wherein, an increase in the amount of the label in the phagocytes in the presence of the test compound compared to the amount of the label present in the phagocytes cultured with FC-induced necrotic macrophages in the absence of the test compound indicates that the compound is an enhancer of phagocytic clearance of a FC-induced necrotic macrophages.

8. The method of claim 2, wherein the FC-induced necrotic macrophage is labeled with annexin V.

9. The method of claim 2, wherein the FC-induced necrotic macrophage is labeled with propidium iodide.

11. The method of claim 2, wherein the necrotic macrophage is induced by contacting the macrophage with acetyl-low density lipoprotein (acetyl-LDL) and an acyl-coenzyme A:

cholesterol acyltransferase (ACAT) inhibitor.

12. The method of claim 2, wherein the cholesterol-loaded macrophage is induced by contacting the macrophage with acetyl-low density lipoprotein (acetyl-LDL) and an acyl-coenzyme A:

cholesterol acyltransferase (ACAT) inhibitor.

36. The composition of claim 34, wherein the phagocyte enhancer compound is identified using the method of any of claim 2.

40. A kit comprising a composition comprising an enhancer of phagocytic clearance of FC-induced necrotic macrophages identified using the method of claim 2, and instructions for use.

3. A method for identifying an enhancer of phagocytic clearance of free cholesterol-loaded macrophages, the method comprising

(a) labeling a free cholesterol-loaded macrophage;

(b) culturing the free cholesterol-loaded macrophage in the presence of phagocytes and in the presence of a test compound, thereby providing a test sample; and

(c) determining the amount of a label present in the phagocytes in the test sample, wherein, an increase in the amount of the label in the phagocytes in the presence of the test compound compared to the amount of the label present in the phagocytes cultured with free cholesterol-loaded macrophages in the absence of the test compound indicates that the compound is an enhancer of phagocytic clearance of a free cholesterol-loaded macrophages.

4. The method of claim 3, wherein the free cholesterol-loaded macrophage is a foam cell.

37. The composition of claim 34, wherein the phagocyte enhancer compound is identified using the method of any of claim 3.

41. A kit comprising a composition comprising an enhancer of phagocytic clearance of free cholesterol-loaded macrophages identified using the method of claim 3, and instructions for use.

16. A method for promoting clearance of apoptotic macrophages from advanced atherosclerotic lesions, the method comprising contacting an atherosclerotic lesion with a compound that promotes clearance of apoptotic macrophages.

17. The method of claim 16, wherein the compound is a lipoxin, a lipoxin analog, a compound that stimulates lipoxin synthesis or activity, an annexin-1, an apolipoprotein E, a RhoA inhibitor, a RhoA kinase inhibitor, a thiazolinedione, interleukin-4, interleukin-13, a corticosteroid, eotaxin, yeast cell wall extract, P1-glucan, acemannan, tuftsin, a C1qRp ligand, an activator of 11-beta-hydroxysteroid dehydrogenase, a CCAAT/enhancer binding protein alpha, and inhibitor of farnesylation, an inhibitor of geranylgeranylation, or a compound that inhibits expression or activity of Cdc44.

18. The method of claim 16, wherein the method further comprises contacting the atherosclerotic lesion with a statin.

19. A method for treating atherosclerosis or inhibiting the development of atherosclerosis in a subject, the method comprising administering to the subject a compound that enhances macrophage phagocytosis.

23. The method of any of claim 19-22, wherein the compound comprises an annexin-1.

24. The method of any of claim 19-22, wherein the compound is an apolipoprotein E.

25. The method of any of claim 19-22, wherein the compound is interleukin-4 or interleukin-13.

26. The method of any of claim 19-22, wherein the compound is a peptidomimetic, a truncation product, or a fragment of an annexin-1, a lipoxin, or an apoplipoprotein E.

27. The method of any of claim 19-22, wherein the compound is a histidine-rich glycoprotein (HRG).

28. The method of any of claim 19-22, wherein the compound inhibits a RhoA or a RhoA kinase.

29. The method of claim 28, wherein the compound is fasudil or Y-27632.

30. The method of any of claim 19-22, wherein the compound is a thiazolinedione, a yeast cell wall extract, P1-glucan, acemannan, tuftsin, a C1qRp ligand, an activator of 11-beta-hydroxysteroid dehydrogenase, a CCAAT/enhancer binding protein alpha, and inhibitor of farnesylation, an inhibitor of geranylgeranylation, or a compound that inhibits expression or activity of Cdc44.

31. The method of any of claim 19-22, wherein the subject is characterized as having a history of heart disease, having diabetes, having atherosclerosis, or any combination thereof.

32. The method of any of claim 19-22, wherein the compound is a lipoxin.

33. The method of any of claim 19-22, wherein a statin is administered to the subject.

20. A method for treating a subject at risk of having or having an atherosclerotic lesion, the method comprising administering to the subject a pharmaceutically effective amount of a compound that promotes clearance of apoptotic macrophages from advanced atherosclerotic lesions.

21. A method for treating a subject at risk of having or having an atherosclerotic lesion, the method comprising administering to the subject a pharmaceutically effective amount of a compound that promotes clearance of necrotic macrophages from advanced atherosclerotic lesions.

22. A method for treating a subject at risk of having or having an atherosclerotic lesion, the method comprising administering to the subject a pharmaceutically effective amount of a compound that promotes clearance of cholesterol-loaded macrophages from advanced atherosclerotic lesions.

34. A composition comprising an enhancer of phagocytic clearance of apoptotic macrophages (a phagocyte enhancer compound) and a pharmaceutically acceptable excipient.

38. The composition of claim 34, further comprising a statin.